Paul Scigalla

Dr. Scigalla is a physician and medical researcher with more than 30 years of clinical development experience across multiple therapeutic areas. As head of Clinical Research for nephrology, oncology and bone metabolism at Boehringer Mannheim GmbH, now Roche Diagnostics GmbH, he was responsible for the preclinical and clinical development of erythropoietin and approval of ibandronate for the treatment osteoporosis and bone metastases. He later served as Head of Global Development Therapeutics and Executive Vice President at SUGEN, Inc., responsible for the clinical development of multiple receptor tyrosine kinase inhibitors, including sunitib (Sutent®) and as Vice President Research Oncology, Pharmacia/Pfizer, Inc. in Bedminster, New Jersey. Since August 2003, he has served as a consultant to several pharmaceutical companies in US, Japan and Europe. Dr. Scigalla received his medical training from the University of Humboldt and was appointed Professor of Medicine from the University of Heidelberg in 1992.